MGMT and central nervous system cancer: Studies on gliomas and glioblastomas have demonstrated a marked increase in the use of AI over the past few years for a variety of purposes, including diagnosis, grading, the prediction of molecular markers such as IDH genotype and MGMT promoter methylation status, prediction of survival, response to treatment, and even understanding functional networks.